![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 18, 15237-15240, May 3, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the
Received for publication, January 16, 2002, and in revised form, February 25, 2002
Neuronal Cdc2-like kinase (Nclk) plays an
important role in a variety of cellular processes, including neuronal
cell differentiation, apoptosis, neuron migration, and formation of
neuromuscular junction. The active kinase consists of a
catalytic subunit, Cdk5, and an essential regulatory subunit, neuronal
Cdk5 activator (p35nck5a or
p25nck5a), which is expressed primarily
in neurons of central nervous tissue. In our previous study using the
yeast two-hybrid screening method, three novel
p35nck5a-associated proteins were isolated.
Here we show that one of these proteins, called C42, specifically
inhibits the activation of Cdk5 by Nck5a. Co-immunoprecipitation data
suggested that C42 and p35nck5a could form a
complex within cultured mammalian cells. Deletion analysis has mapped
the inhibitory domain of C42 to a region of 135 amino acids, which is
conserved in Pho81, a yeast protein that inhibits the yeast
cyclin-dependent protein kinase Pho85. The Pho85·Pho80
kinase complex has been shown to be the yeast functional
homologue of the mammalian Cdk5/p35nck5a kinase.
Cyclin-dependent protein kinases
(Cdks)1 play critical roles
in the regulation of cell division (1). As the name implies, functional Cdks require binding of a cyclin for kinase activity. In
addition to depending on cyclin for activity, Cdk activities are
regulated by complex mechanisms including protein phosphorylation and
association with specific Cdk inhibitors. There are two Cdk inhibitor
families: INK4 and Kip/Cip. Crystallography analysis has shown that the
INK4 family member p16INK4a causes the kinase
inhibition by direct association to Cdk4 (4). On the other hand,
p27Kip/Cip binds to both Cdk2
and cyclin A in the Cdk2·cyclin A complex to inhibit the kinase
activity (5).
Cyclin-dependent kinase 5 is unique among Cdks in many
respects. Unlike most other Cdks, Cdk5 has no known function in the cell division cycle but is involved in the regulation of neuronal differentiation and neurocytoskeleton dynamics (6-10). There are two
mammalian Cdk5 activators: neuronal Cdk5 activator,
p35nck5a, and neuronal Cdk5 activator isoform,
p39nck5ai; both Nck5a and Nck5ai are expressed
predominantly in neurons of central nervous systems (11, 12, 20). While
Nck5a and Nck5ai are homologous proteins, they show little or no
sequence similarity to cyclins. Members of both Cdk inhibitor families have been tested and shown to have no activity toward Cdk5. Biochemical analysis of Cdk5 in bovine brain extract suggests the existence of an
inhibitory factor that exists together with Cdk5 and
p35nck5a in a protein complex (13). However, the
molecular identity of the factor has not been established. In
Saccharomyces cerevisiae, there is a
cyclin-dependent protein kinase, Pho85, and its cyclin partner Pho80, which have been shown to be the functional homologues of
mammalian Cdk5 and Nck5a, respectively (14). In addition, there is a
specific Pho80/Pho85 inhibitor protein, Pho81, whose mammalian
functional homologue is not known.
Recently we have used the yeast two-hybrid system to screen for the
p35nck5a-associated protein (15). Among the
positive clones are three clones, called C42, C48, and C53, whose
cDNA sequences are novel (16). In the present study, we show that
one of the novel proteins, C42, displays an inhibitory effect on Cdk5
kinase activity. Interestingly, while both the full-length C42 and the
C42 fragment obtained from the yeast two-hybrid screen can bind Nck5a,
only the full-length protein has Cdk5 inhibitory activity. Using
deletion mutants, we have mapped the inhibitory domain of C42 to a
135-amino acid region, which shows a significant homology to the
inhibitory region of Pho81.
Cloning and Construction of Plasmids--
The DNA fragment
encoding full-length C42 (C42-FL) and C42 binding fragment
were subcloned into pCMV-Myc (CLONTECH) via
EcoRI/NotI and XhoI/KpnI
sites, respectively. To generate the deletion mutants of C42, the
pGEX-C42-FL plasmid was digested with NheI/NotI
for the N56 mutant, SmaI for the N168 mutant,
XbaI/NotI for the N279 mutant,
StyI/NotI for the N360 mutant, and
HindIII/NotI for the N492 mutant, filled in at
the adhesive end, and re-ligated. To make the
FLAG-p35nck5a expression construct, the
DNA encoding p35nck5a was retrieved by
digestion with HindIII, filled in, and then cut with
BamHI. The BamHI/blunt DNA fragment was ligated
into pFLAG-CMV2 (Kodak) via BamHI/SmaI sites.
Purification of the Proteins--
The glutathione
S-transferase (GST) fusion forms of C42, Cdk5, and Cdk2
proteins were purified according to a previous protocol (17). p25, p35,
and p39 were subcloned into the pET32 vector, and His-tagged proteins
were purified using the nickel-nitrilotriacetic acid beads (Invitrogen).
Cell Culture and Transfection--
HeLa cells were maintained in
Dulbecco's modified Eagle's medium containing 10% fetal bovine serum
at 37 °C in a humidified atmosphere at 5% CO2.
Transient transfection was carried out using LipofectAMINE Plus reagent
(Invitrogen). Cells were incubated for 24 h before
harvesting. The cells were washed twice in PBS and lysed with 100 µl
of lysis buffer (50 mM Hepes, pH 7.2, 250 mM
NaCl, 0.1% Nonidet P-40, 1 mM EDTA, 1 mM EGTA,
5 mM sodium fluoride, 10 µg/ml leupeptin, 1 µg/ml
antipain, 2 mM phenylmethylsulfonyl fluoride, and 100 µg/ml benzamidine) for 15 min at 4 °C. Protein concentration
was determined by the Bradford assay (Bio-Rad).
Affinity Binding Assay--
The GST fusion form of C42 protein
(20 µg) was incubated with His-tagged p35nck5a
(1 µg) for 30 min followed by addition of GST-free Cdk5 (1 µg) and
incubation for another 30 min at 30 °C. After 20 µl (50% slurry) of GSH-agarose beads (Amersham Biosciences) were added to the mixture
and kept on ice for 1 h, beads were washed four times with 1 ml of
PBS. The bound proteins were released by addition of 2× SDS loading buffer.
In Vitro Kinase Assay--
The Cdk5 kinase assay was performed
according to the method described previously (18). Since the GST-C42
full-length preparation was contaminated with degraded forms, the molar
concentration indicated was a calculated proportion of the GST-C42
protein band to the total protein used. For the protein substrate
assay, the reactions were stopped by addition of 2× SDS loading
buffer, and the proteins were resolved by 15% SDS-PAGE.
Immunoprecipitation and Western Blotting--
For
immunoprecipitation, antibodies were incubated with transfected cell
lysate at 4 °C for 1 h before the addition of protein G-Sepharose beads. For immunoblotting, blots were visualized by enhanced chemiluminescence according to the manufacturer's procedure (Amersham Biosciences). Anti-Cdk5 (C-8), anti-c-Myc (A-14), and anti-p35 (C-19) antibodies were obtained from Santa Cruz
Biotechnologies, and anti-FLAG (M2) antibody was obtained from Sigma.
Inhibition of Nck5a Activating Activity of Cdk5 Kinase by
Full-length C42 Protein--
The C42 clone obtained from the yeast
two-hybrid screen encodes a polypeptide of 112 amino acid residues
corresponding to Glu475-Thr586 (the C
terminus). This polypeptide displays high affinity Nck5a binding and is
referred to as C42-BF. The C42-FL and C42-BF were bacterially expressed
in GST fusion forms and tested for their effect on Cdk5 kinase
activity. Fig. 1Ai shows that
C42-FL inhibited Cdk5 kinase markedly in a dose-dependent
manner, whereas the C42-BF or the GST protein has little effect on Cdk5
activity. The full-length form of the other two novel binding proteins,
i.e. C48 and C53, were also tested and found to have no Cdk5
kinase inhibitory activity (data not shown). Western immunoblot
analysis of the incubation reaction sample showed that quantities of
Cdk5 and the activator remained unchanged after incubating with
increasing amounts of C42-FL protein (Fig. 1Aii), suggesting
that the loss of Cdk5 kinase activity could not be attributed to the
possible contamination of proteases in the C42-FL sample.
The C42 inhibition of Cdk5 depends on the order of addition of C42 to
the Cdk5 activation reaction. The kinase inhibition could be readily
observed if C42 was incubated with p35nck5a
prior to the addition of Cdk5 or if the three proteins, C42, p35nck5a, and Cdk5, were mixed simultaneously.
On the other hand, preincubation of Cdk5 with
p35nck5a markedly lowered the inhibitory effect
of C42 (Fig. 1B). To examine whether
p35nck5a could still form a complex with Cdk5
after binding with C42 protein, affinity pull-down experiments were
performed. A sample of p35nck5a preincubated
with the GST-fused full-length C42 or C42 fragment was tested for the
ability to associate with Cdk5. As shown in Fig. 1C, both
GST-C42-FL·p35nck5a and
GST-C42-BF·p35nck5a preformed complexes were
able to pull down Cdk5. In some experiments, a small amount of Cdk5 was
found to co-precipitate with the GST control. The reason for this is
not clear. In contrast to p35nck5a-bound
GST-C42, free GST-C42, either the full-length or the fragment, did not
pull down Cdk5 in the affinity binding assay (data not shown). The
observation that the full-length C42·p35nck5a
complex can bind Cdk5 indicates that C42 inhibition is not due to a
competition between C42 and Cdk5 for p35nck5a binding.
To test whether or not C42 protein could associate with Nck5a within
mammalian cells, co-immunoprecipitation experiments were carried out.
The full-length C42 or the C42 fragment was transfected into HeLa cells
and expressed as Myc-tagged protein together with FLAG-tagged
p35nck5a and His-tagged Cdk5. Transfected cell
lysates, which contained similar amounts of the expressed proteins,
were selected for the co-immunoprecipitation experiment (Fig.
1Di). As shown in Fig. 1Dii, the Myc-C42 (either
the full-length protein or C42 fragment) and Cdk5 were found in the
immunoprecipitates from the triple transfected cell lysates,
i.e. lysates from cells transfected with
p35nck5a/C42/Cdk5, in the anti-p35
antibody-mediated precipitation. On the other hand, the
immunoprecipitates from the control cell lysates, i.e.
lysates from cells transfected with C42/Cdk5 and
p35nck5a/Cdk5, did not contain Myc-C42. These
results suggest that p35nck5a can form a complex
with C42 and Cdk5 inside the cells. However, attempts to use anti-Myc
antibody for immunoprecipitation were not successful because the
antibody did not precipitate the Myc-tagged C42 protein effectively
even when an excessive amount of the antibody was used (data not shown).
Specificity of the Inhibition of
p35nck5a/Cdk5 by C42--
A series of experiments were
carried out to test the specificity of the kinase inhibition activity
of C42. Cyclin A-activated Cdk2 has catalytic properties similar to
p35nck5a/Cdk5 kinase. Fig.
2A shows that although
co-incubation of the full-length C42 with Cdk5 and
p35nck5a abolished almost 90% of the kinase
activity, co-incubation of Cdk2 and cyclin A with C42 protein had
little or no effect on Cdk2 activity. Nck5a exists in the brain or cell
extracts in a 35-kDa or a 25-kDa form, and both forms of the protein
associate with Cdk5 (11, 12, 19). Furthermore, mammalian brains contain an isoform of Nck5a, p39nck5ai, that also
associates with and activates Cdk5 (20). To further test the C42
inhibition specificity, the effects of C42 on Cdk5 activated by these
various forms of activator proteins were examined. As shown in Fig.
2B, C42 is capable of inhibiting Cdk5 irrespective of the
form of the activator protein used. An early study had shown
that Nck5a, in addition to activating Cdk5, can also activate Cdk2
albeit to an activity level much lower than that achieved by cyclin A
(17). Fig. 2C shows that although cyclin A-activated Cdk2
was refractory to C42 inhibition,
p35nck5a-activated Cdk2 was efficiently
inhibited by the full-length C42. In addition to demonstrating the
specificity of C42 inhibition toward p35nck5a,
these results rule out the possibility that the loss of kinase reaction
is attributed to the existence of protease, ATPase, or phosphatase
activity in the C42 sample.
Identification of the N-terminal Inhibitory Region of
C42--
To map the inhibitory domain of C42, a series of C-terminal
deletion mutants were generated, including N492, N360, N168, and N56
(the number refer to the residues left from the N-terminal). All of the
mutants were able to inhibit the p35nck5a/Cdk5
kinase activity except N56 (Fig.
3A) (data not shown for the
N492 mutant). The result indicates that the Cdk5 inhibitory domain is
contained in the N-terminal region (residues 1-168) of the C42
protein. This region does not contain the sequence corresponding to
C42-BF, thus suggesting the existence of separate Nck5a-binding and
Cdk5 inhibition domains in C42. S. cerevisiae protein Pho81
displays specific inhibitory activity toward the yeast Cdk5/Nck5a
homologue, i.e. Pho85/Pho80. Alignment of C42 and Pho81 has
revealed a moderate sequence homology (19% identity and 56.8%
similarity). Recently the inhibitory domain of Pho81 has been
identified to comprise about 80 residues, residues 645-724 (21). When
this domain was compared with the full-length C42 protein sequence, it
aligned to the N-terminal region of C42 from residues 22-157 (Fig.
3B). Note that this is within the N-terminal region of C42
(residues 1-168) expected to contain the Cdk5 inhibitory domain.
To further test whether the region comprising residues 22-157 of C42
is the Cdk5 inhibitory domain, this portion of C42 was expressed
bacterially and tested for Cdk5 inhibitory activity. As shown
in Fig. 3, C and D, the GST fusion
form of the inhibitory domain can suppress the phosphorylation of both
protein and peptide substrates by Cdk5 kinase. In the assay using
histone H1 protein as substrate, addition of C42 inhibitory domain had
reduced about 60% of the Cdk5 kinase activity (Fig.
3D).
Previously we have used the yeast two-hybrid screen to isolate
three novel p35-binding proteins, named C42, C48, and C53, and showed
that they bind to p35nck5a·Cdk5 complex (16).
In this study, we demonstrate that the full-length C42, but not the C42
fragment from the yeast two-hybrid screen, possesses potent inhibitory
activity toward Cdk5. We have carefully ruled out a number of artifacts
that may give rise to an apparent kinase inhibition, such as the
contamination of protease, ATPase, or phosphatase activity in the C42
sample. Affinity precipitation using bacterially expressed proteins
indicates that either full-length C42 or C42 fragment can form a
ternary complex with Cdk5 and Nck5a. Immunoprecipitation analysis shows
that the ternary complexes can also exist in HeLa cell lysates. These
results strongly suggest that C42 is a Cdk5 inhibitor. In fact, we have
carried out transfection experiments showing that ectopic expression of
the full-length C42 in NG108 neuroblastoma cells markedly suppressed
the differentiation of the cells in differentiating medium, whereas
the expression of C42-BF had significantly less
effect.2
The amino acid sequence of C42 shows no sequence similarity to proteins
of either CKI family. The mechanism of Cdk5 kinase inhibition of C42
also appears to distinguish the protein from the known CKIs. While CKIs
of the Kip/Cip family interact through the kinase catalytic subunit,
members of the INK4 family undergo physical interactions with both the
kinase and the cyclin subunits. In contrast, C42 appears to inhibit
Cdk5 activity by interacting exclusively with the regulatory subunit
Nck5a (or Nck5ai). Affinity binding experiments have shown that C42
undergoes high affinity binding to both Nck5a (or Nck5ai) and the
Nck5a·Cdk5 complex but not to monomeric Cdk5. The inhibitory activity
of C42 shows a strict specificity toward Nck5a or Nck5ai rather than
the kinase subunit. This may be demonstrated by using Cdk2 instead of
Cdk5 as the inhibition target. Only the
p35nck5a-activated Cdk2 but not the cyclin
A-activated Cdk2 can be inhibited by C42.
While there is a good correlation between C42 inhibition activity and
the ability of the protein to undergo high affinity binding to Cdk5
activator proteins, the inhibition activity is not solely due to the
protein binding. Both full-length C42 and the C42 fragment bind to
Nck5a with high affinity, but only the full-length C42 displays
kinase inhibitory activity. Despite the fact that the other two novel
Nck5a-binding proteins, C48 and C53, share the same Nck5a binding
region of C42, they did not exhibit Nck5a inhibitory activity. These
observations have led us to speculate that the full-length C42 contains
a kinase inhibitory domain in addition to the high affinity
Nck5a-binding domain. Deletion analysis has suggested the existence of
a kinase inhibitory domain distinct from the Nck5a-binding domain of
C42, a suggestion subsequently confirmed from sequence comparison
between C42 and the recently identified Cdk inhibition domain in Pho81
(see below). A simple model to account for the existence of both
Nck5a-binding and kinase inhibition domains is that while kinase
inhibition depends solely on the kinase inhibitory domain, C42 uses the
high affinity Nck5a-binding domain to increase the affinity of the inhibitory domain-enzyme interaction. The fact that the inhibitory domain can only inhibit about 60% of the kinase activity may suggest that the Nck5a-binding domain is required for achieving high inhibitory activity. This is also in agreement with the observation that the
concentration of the inhibitory domain required for kinase inhibition
is about an order of magnitude higher than that of full-length C42.
A number of observations suggest that C42 is related to Pho81, a Cdk
inhibitor that is specific for Pho85/Pho80, the yeast homologue of
Cdk5/Nck5a. The kinase inhibitor domain of Pho81 has recently been
mapped (21). Sequence alignment of C42 and Pho81 has identified
a region in C42 showing significant similarity to the kinase inhibitory
domain of Pho81. The C42 deletion mutant containing only this region of
the protein displayed Cdk5 inhibitory activity. In addition to
structural similarity, C42 and Pho81 are similar in their Cdk
inhibition mechanisms. Results of complementary assays in yeast
suggested that Cdk5 could associate with Pho80 to form an active kinase
and that the active kinase responded to Pho81 in yeast growing in low
phosphate medium. Like C42, Pho81 exerts its kinase inhibitory activity
through interaction with the regulatory subunit Pho80, rather than with
Pho85, the catalytic (Cdk) subunit. The kinase inhibition by C42 is
strongly dependent on the order of addition of Cdk5 to Nck5a and Cdk5
(Fig. 1B). Intriguingly a ternary complex of Cdk5, Nck5a,
and C42 can be formed under either the inhibiting or the noninhibiting
conditions. Based on their functional analysis of Pho81 and Pho85/Pho80
interaction in yeast cells, Huang et al. (21)
suggested that Pho81 might form either an active or an inactive ternary
complex with Pho85/Pho80 kinase in high and low phosphate medium. Thus,
from these various lines of evidence, it is suggested that C42 and
Pho81 may be grouped into a new family of CKIs.
*
This work was supported by a grant from the Research Grants
Council of Hong Kong and Hong Kong AoE of Molecular Neuroscience.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Current address: Inst. of Molecular Biology, Hong Kong University,
Pokfulam, Hong Kong, China.
**
To whom correspondence should be addressed. Tel.: 852-2358-8701;
Fax: 852-2358-1552; E-mail: jerwang@ust.hk.
Published, JBC Papers in Press, March 6, 2002, DOI 10.1074/jbc.C200032200
2
Y.-P. Ching, W.-H. Lam, and J. H. Wang,
unpublished observation.
The abbreviations used are:
Cdk, cyclin-dependent protein kinase;
Nck5a, neuronal
cyclin-dependent protein kinase 5 activator;
Nclk, neuronal
Cdc2-like kinase;
GST, glutathione S-transferase;
FL, full
length;
BF, binding fragment;
PBS, phosphate-buffered saline;
MOPS, 4-morpholinepropanesulfonic acid;
CKI, cyclin kinase
inhibitor.
ACCELERATED PUBLICATION
Identification of a Neuronal Cdk5 Activator-binding Protein as
Cdk5 Inhibitor*
§,
,
,
, and
**
Department of Biochemistry, Hong Kong
University of Science and Technology, Clear Water Bay, Kowloon, Hong
Kong, China and the ¶ Department of Medical Biochemistry, Faculty
of Medicine, University of Calgary, Calgary,
Alberta T2N 1N4, Canada
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
![]()
MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

View larger version (26K):
[in a new window]
Fig. 1.
Inhibition of Cdk5 kinase activity by
full-length C42 protein. Ai, increasing amounts of
full-length (C42-FL, open diamond) and binding
fragment (C42-BF, solid diamond) of C42 proteins
in GST fusion form were incubated with His6-p35 (0.5 µg)
and GST-Cdk5 (1 µg) for 30 min at 30 °C before being assayed for
the histone H1 kinase activity as described under "Materials and
Methods." GST (open circle) protein was used as a control.
Aii, an aliquot ( 
). The protein
complexes after incubation were precipitated by GSH-agarose beads,
transferred, and immunoblotted with anti-Cdk5 and anti-p35 antibodies.
D, co-immunoprecipitation of C42 and p35. Di,
HeLa cells were co-transfected with constructs expressing His-Cdk5,
FLAG-p35, Myc-C42-FL, and Myc-C42-BF. 10 µg of the transfected cell
lysates were loaded onto each lane and immunoblotted with anti-Cdk5
(C-8), anti-FLAG (M2), and anti-Myc antibody (A-14). The combination of
plasmids used were: lane 1, p35/Cdk5/C42-BF; lane
2, p35/Cdk5/C42-FL; lane 3, Cdk5/C42-BF; lane
4, Cdk5/C42-FL; lane 5, p35/Cdk5; lane 6 p35/C42-BF; lane 7, p35/C42-FL, and lane 8,
vector control. Dii, monoclonal anti-FLAG (M2) antibody was
used to immunoprecipitate the p35 from the transfected cell lysates,
and immunoprecipitants were loaded onto the SDS-polyacrylamide gel.
Western blotting was performed using the specific polyclonal
antibodies, i.e. anti-Cdk5 (C-8), anti-p35 (C-19), and
anti-Myc (A-14) antibodies. The loading sequence of the samples was the
same as in A.

View larger version (17K):
[in a new window]
Fig. 2.
Specific inhibition of Nck5a by C42
protein. A, GST-Cdk2 (1 µg)/His6-cyclin A
(0.5 µg) and GST-Cdk5 (1 µg)/His6-p35 (0.5 µg) were
reconstituted in the presence of increasing concentrations of
full-length GST-C42 protein for 30 min at 30 °C and then assayed for
the histone H1 kinase activity. The activity was expressed as
percentage of control. B, proteins were reconstituted
similar to those in A, but His6-p35 (0.5 µg),
His6-p25 (0.5 µg), and His6-p39 (0.5 µg)
were used to activate GST-Cdk5. For GST control, the GST-C42 was
replaced by an equal amount of GST protein in the assay of
His6-p39·GST-Cdk5 complex. C, proteins were
reconstituted similar to those in A, but GST-Cdk2, instead
of GST-Cdk5, was used for reconstitution with
His6-p35.

View larger version (37K):
[in a new window]
Fig. 3.
Mapping of the inhibitory region of C42.
A, deletion mutants of C42 were assayed for the inhibition
of p35·Cdk5 kinase complex. Different concentrations of the full
length (FL), binding fragment (BF), GST control,
and the mutants including N360, N168, and N56 were reconstituted
similar to proteins in Fig. 2A, and the kinase activity was
assayed as described. B, the inhibitory domain of Pho81 was
aligned with the full-length sequence of C42 by the ClustalW program.
The numbers at the right-hand side of the C42
sequence represent the position of the residue corresponding to the
full-length sequence. Asterisks indicate identical residues,
and semicolons indicate similar residues. C, the
fragment C42-N22-157 was tested for the inhibition of p35·Cdk5
kinase complex. Different amounts of the protein were incubated with
the kinase complex, and the activity was measured using histone H1
peptides. D, the inhibition of Cdk5 kinase activity by the
C42-N22-157 fragment was assayed using histone H1 protein substrate as
described under "Materials and Methods." The phosphorylation of
histone H1 proteins was quantitated by densitometry, and the relative
intensity of the signals in percentage was indicated at the
bottom of the band.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
![]()
FOOTNOTES
Current address: Inst. of Molecular and Cell Biology, 30 Medical Dr., Singapore 117609, Singapore.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
1.
Morgan, D. O.
(1997)
Annu. Rev. Cell Dev. Biol.
13,
261-291[CrossRef][Medline]
[Order article via Infotrieve] 2.
Deleted in proof
3.
Deleted in proof
4.
Jeffrey, P. D.,
Tong, L.,
and Pavletich, N. P.
(2000)
Genes Dev.
14,
3115-3125 5.
Pavletich, N. P.
(1999)
J Mol. Biol.
287,
821-829[CrossRef][Medline]
[Order article via Infotrieve] 6.
Dhavan, R.,
and Tsai, L. H.
(2001)
Nat. Rev. Mol. Cell. Biol.
10,
749-759 7.
Lew, J.,
and Wang, J. H.
(1995)
Trends Biochem. Sci.
20,
33-37[CrossRef][Medline]
[Order article via Infotrieve] 8.
Deleted in proof
9.
Grant, P.,
Sharma, P.,
and Pant, H. C.
(2001)
Eur. J. Biochem.
268,
1534-1546[Medline]
[Order article via Infotrieve] 10.
Deleted in proof
11.
Lew, J.,
Huang, Q. Q., Qi, Z.,
Winkfein, R. J.,
Aebersold, R.,
Hunt, T.,
and Wang, J. H.
(1994)
Nature
371,
423-426[CrossRef][Medline]
[Order article via Infotrieve] 12.
Tsai, L. H.,
Delalle, I.,
Caviness, V. S., Jr.,
Chae, T.,
and Harlow, E.
(1994)
Nature
371,
419-423[CrossRef][Medline]
[Order article via Infotrieve] 13.
Lee, K. Y.,
Rosales, J. L.,
Tang, D.,
and Wang, J. H.
(1996)
J. Biol. Chem.
271,
1538-1543 14.
Huang, D.,
Patrick, G.,
Moffat, J.,
Tsai, L. H.,
and Andrews, B.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
14445-14450 15.
Qi, Z.,
Tang, D.,
Zhu, X.,
Fujita Donald, J.,
and Wang, J. H.
(1998)
J. Biol. Chem.
273,
2329-2335 16.
Ching, Y. P., Qi, Z.,
and Wang, J. H.
(2000)
Gene (Amst.)
242,
285-294[CrossRef][Medline]
[Order article via Infotrieve] 17.
Tang, D.,
Chun, A. C. S.,
Zhang, M.,
and Wang, J. H.
(1997)
J. Biol. Chem.
272,
12318-12327 18.
Lew, J.,
Beaudette, K.,
Litwin, C. M.,
and Wang, J. H.
(1992)
J. Biol. Chem.
267,
13383-13390 19.
Qi, Z.,
Huang, Q. Q.,
Lee, K. Y.,
Lew, J.,
and Wang, J. H.
(1995)
J. Biol. Chem.
270,
10847-10854 20.
Tang, D.,
Yeung, J.,
Lee, K. Y.,
Matsushita, M.,
Matsui, H.,
Tomizawa, K.,
Hatase, O.,
and Wang, J. H.
(1995)
J. Biol. Chem.
270,
26897-26903 21.
Huang, S.,
Jeffery, D. A.,
Anthony, M. D.,
and O'Shea, E. K.
(2001)
Mol. Cell. Biol.
21,
6695-6705 22.
Deleted in proof
23.
Deleted in proof
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
Z. Hou, Q. Li, L. He, H.-Y. Lim, X. Fu, N. S. Cheung, D. X. Qi, and R. Z. Qi Microtubule Association of the Neuronal p35 Activator of Cdk5 J. Biol. Chem., June 29, 2007; 282(26): 18666 - 18670. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. J. Scott, K. L. Mohlke, L. L. Bonnycastle, C. J. Willer, Y. Li, W. L. Duren, M. R. Erdos, H. M. Stringham, P. S. Chines, A. U. Jackson, et al. A Genome-Wide Association Study of Type 2 Diabetes in Finns Detects Multiple Susceptibility Variants Science, June 1, 2007; 316(5829): 1341 - 1345. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Bomeke, R. Pries, V. Korte, E. Scholz, B. Herzog, F. Schulze, and G. H. Braus Yeast Gcn4p Stabilization Is Initiated by the Dissociation of the Nuclear Pho85p/Pcl5p Complex Mol. Biol. Cell, July 1, 2006; 17(7): 2952 - 2962. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C. B. Lim, Z. Hou, C.-P. Goh, and R. Z. Qi Protein Kinase CK2 Is an Inhibitor of the Neuronal Cdk5 Kinase J. Biol. Chem., November 5, 2004; 279(45): 46668 - 46673. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Druker, T. J. Bruxner, N. J. Lehrbach, and E. Whitelaw Complex patterns of transcription at the insertion site of a retrotransposon in the mouse Nucleic Acids Res., November 1, 2004; 32(19): 5800 - 5808. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |